^
ARAF mutation + NRAS mutation
Melanoma
HM95573
Resistant
:
D
Nature - 2d
PD-L1 negative
Melanoma
pembrolizumab + ipilimumab
Sensitive
:
C3
J Clin Oncol - 3d
BRAF V600E
Melanoma
Immunotherapy
Resistant
:
C3
SID 2021 - 2wk
BRAF V600E
Melanoma
trametinib + dabrafenib
Sensitive
:
A1
EADO-WCM 2021 - 3wk
BRAF V600E
Melanoma
vemurafenib + cobimetinib
Sensitive
:
A1
EADO-WCM 2021 - 3wk
BRAF V600E
Melanoma
vemurafenib
Sensitive
:
A1
EADO-WCM 2021 - 3wk
BRAF V600E
Melanoma
binimetinib + encorafenib
Sensitive
:
A1
EADO-WCM 2021 - 3wk
PD-L1 expression
Cutaneous Melanoma
pembrolizumab
Sensitive
:
B
The Lancet - 3wk
BRAF V600E
Melanoma
nivolumab + ipilimumab
Sensitive
:
C2
EADO-WCM 2021 - 3wk
NRAS Q61R
Melanoma
nivolumab + ipilimumab
Sensitive
:
C4
EADO-WCM 2021 - 3wk
BRAF V600E
Melanoma
encorafenib + S63845
Sensitive
:
D
EADO-WCM 2021 - 3wk
NRAS mutation
Melanoma
binimetinib + encorafenib
Sensitive
:
D
EADO-WCM 2021 - 3wk
No biomarker
BCC
fluorouracil topical
Sensitive
:
A1
BRAF V600
Melanoma
vemurafenib + atezolizumab + cobimetinib
Sensitive
:
A1
BRAF V600E
Melanoma
dabrafenib
Sensitive
:
A1
BRAF V600
Melanoma
binimetinib + encorafenib
Sensitive
:
A1
BRAF V600K
Melanoma
trametinib + dabrafenib
Sensitive
:
A1
No biomarker
Melanoma
pembrolizumab
Sensitive
:
A1
BRAF V600
Melanoma
vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600E
Melanoma
trametinib
Sensitive
:
A1
No biomarker
Melanoma
nivolumab
Sensitive
:
A1
No biomarker
BCC
vismodegib
Sensitive
:
A1
No biomarker
Merkel Cell Carcinoma
avelumab
Sensitive
:
A1
No biomarker
Merkel Cell Carcinoma
pembrolizumab
Sensitive
:
A1
No biomarker
BCC
imiquimod
Sensitive
:
A1
No biomarker
Melanoma
ipilimumab
Sensitive
:
A1
No biomarker
Melanoma
nivolumab + ipilimumab
Sensitive
:
A1
PD-L1 underexpression
Melanoma
ipilimumab
Sensitive
:
A1
PD-L1 underexpression
Melanoma
nivolumab + ipilimumab
Sensitive
:
A1
BRAF V600
Melanoma
dabrafenib
Sensitive
:
A1
No biomarker
Melanoma
trametinib
Resistant
:
A1
BRAF V600
Melanoma
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600
Melanoma
trametinib
Sensitive
:
A1
BRAF V600K
Melanoma
trametinib
Sensitive
:
A1
BRAF V600
Melanoma
vemurafenib
Sensitive
:
A1
No biomarker
BCC
sonidegib
Sensitive
:
A1
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our